- Takeda fortifies orexin potential with more Phase 3 dataWith a formidable new competitor set to enter the orexin development race, Takeda is out with new data that it hopes will reinforce market-leading potential. The additional results from Takeda’s tw…Endpoints · 1mo ago↗ source
- Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummetElicio Therapeutics’ pancreatic cancer vaccine failed to improve outcomes in a mid-stage study, but the company is seeking funds to move ahead to a larger Phase 3 trial anyway. Elicio reported ...Endpoints · 1mo ago↗ source
- STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to endAfter July 1, Medicare will offer GLP-1 weight-loss drugs for $50. It's supposed to be temporary, but chances are it won't be.